Rituximab add-on therapy for breakthrough relapsing MS

A board to discuss the anticipated multiple sclerosis treatment Rituxan.

Rituximab add-on therapy for breakthrough relapsing MS

Postby MSUK » Wed Jun 16, 2010 7:49 am

Rituximab add-on therapy for breakthrough relapsing MS: a 52-week phase II trial



B cells and the humoral immune system have been implicated in the pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety, and tolerability of add-on therapy with rituximab, a monoclonal antibody that depletes circulating B cells, in subjects with relapsing MS with breakthrough disease defined by clinical and MRI activity (Class III evidence).

METHODS: Thirty subjects with a relapse within the past 18 months despite use of an injectable disease-modifying agent, and with at least 1 gadolinium-enhancing (GdE) lesion on any of 3 pretreatment MRIs, received rituximab administered at 375 mg/m(2) weekly x 4 doses. Three monthly posttreatment brain MRI scans were obtained beginning 12 weeks after the first infusion. Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) were obtained at baseline and throughout the post-treatment follow-up. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1394
MS-UK - http://www.ms-uk.org/
User avatar
Family Elder
Posts: 2483
Joined: Wed Oct 14, 2009 3:00 pm


Return to Rituxan (Rituximab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service